Table 4.
Study | Year, design | N | Median age, years | Median PSA, ng/mL | Risk group | Median prostate volume, cc | Dose (Gy)/fractions | Median f/u, M | BCRFSb (%) | Late toxicity (%) | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
GI/GU | G2 | G3 | G4 | ||||||||||
Aluwini13 | 2013, P | 50 | 68a | 8.2a | L, I | 48a | 38 and 44 (DIL)/4 | 23 | 2Y, 100 (L, I) | GI | 3 | 0 | 0 |
GU | 10 | 6 | 0 | ||||||||||
Freeman8 | 2011, P | 41 | 66 | 5.6 | L | NA | 35–36.25/5 | 60 | 5Y, 93 | GI | 2.5 | 0 | 0 |
GU | 7 | 2.5 | 0 | ||||||||||
Katz9 | 2014, R | 515 | 69.5 | 5.4 | L, I, H | 59.15 | 35–36.25/5 | 72 | 7Y, 95.8 (L), 89.3 (I), 68.5 (H) | GI | 4 | 0 | 0 |
GU | 9.1 | 1.7 | 0 | ||||||||||
Davis10 | 2015, R | 437 | 69 | 5.8 | L, I, H | 52 | 35–38/5 | 20 | 2Y, 99 (L), 94.5 (I), 89.8 (H) | GI | 2 | 0 | 0 |
GU | 2–8 | 0 | 0 | ||||||||||
Hannan11 | 2016, P | 91 | 66 | 5.4 | L, I | 33 | 45–50/5 | 54 | 5Y, 90.9 (45 Gy), 100 (47.5–50 Gy) | GI | 13.2 | 4.4 | 2.2 |
GU | 20.9 | 4.4 | 1.1 | ||||||||||
Kishan12 | 2019, R | 2,142 | 68 | 5.7 | L, I | NA | 33.5–40/4–5 | 83 | 7Y, 95.5 (L), 89.8 (I) | GI | 4.5 | 0.4 | |
GU | 12.3 | 2.4 |
BCRFS biochemical recurrence-free survival, DIL dominant intraprostatic lesion, f/u follow-up, G grade, GI gastrointestinal, GU genitourinary, H high, I intermediate, L low, M months, N numbers, NA not available, P prospective, PSA prostate specific antigen, R retrospective, Y year(s).
aReported as mean values.
bBiochemical recurrence was defined according to Phoenix definition (nadir + 2 ng/mL) in all studies.